SCHEMBL5553397

SCHEMBL5553397

O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCC2(CC1)C(=O)N(c1ncccn1)CN2c1ccccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 7/20 0.54
CYP2C9 P11712 5/20 0.54
CYP2D6 P10635 4/20 0.53
HSD17B10 Q99714 3/20 0.53
CYP2C19 P33261 3/20 0.53
TSHR P16473 7/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
CYP3A4 P08684 8/20 0.50
CYP1A2 P05177 4/20 0.50
DDR1 Q08345 4/20 0.50
ALDH1A1 P00352 2/20 0.50
HIF1A Q16665 2/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
OPRD1 P41143 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5553192 0.92 DDR1 (0.49) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5559643 0.89 CYP3A4 (0.55) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5558411 0.87 DDR1 (0.58) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5557809 0.87 DDR1 (0.48) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5553468 0.87 DDR1 (0.48) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5557761 0.86 DDR1 (0.53) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5557592 0.86 DDR1 (0.51) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5557758 0.85 CYP3A4 (0.51) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5559756 0.82 DDR1 (0.57) USP2CYP2C9CYP2D6HSD17B10CYP2C19
SCHEMBL5553306 0.81 DDR1 (0.51) USP2TSHRSMN1; SMN2CYP3A4DDR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US claimed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US claimed
EP-1292596-B1 1,3,8-TRIAZA-SPIRO¬4,5 DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US disclosed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor TACR1, TACR2, NPR1 USP2 3849/4885CYP2C9 2859/4885CYP2D6 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.